ANTIOXIDANT ACTIVITIES OF ROPINIROLE AND PRAMIPEXOLE NOVEL DRUGS USED IN TREATMENT OF PARKINSONISM: AN IN VITRO APPROACH

Preetha Selva; Srinivasan Vengadassalapathy

doi:10.22159/ajpcr.2016.v9s3.14861

Authors

Preetha Selva Department of Pharmacology Saveetha Medical College Saveetha University Saveetha Nagar Thandalam Chennai-602105
Srinivasan Vengadassalapathy Department of Pharmacology Saveetha Medical College Saveetha University Saveetha Nagar Thandalam Chennai-602105

DOI:

https://doi.org/10.22159/ajpcr.2016.v9s3.14861

Abstract

ABSTRACT
Objective: The objective of this study is to evaluate and compare the free radical scavenging activities of selective dopamine agonist namely ropinirole
and pramipexole.
Methods: The antioxidant activity of ropinirole and pramipexole at various concentrations was done by 1, 1-diphenyl-2picrylhydrazyl (DPPH) free
radical scavenging assay comparing it with ascorbic acid which was taken as standard.
Results: The free radical scavenging property as measured by DPPH method showed that ropinirole and pramipexole have got a potent free radical
scavenging activity with that of ascorbic acid.
Conclusion: Novel drugs such as pramipexole and ropinirole are promising molecules in the field of oxidative damage related neurodegenerative
disorders providing us an optimistic targeted approach toward neuroprotection.
Keywords: Free radical scavenging, 1, 1-diphenyl-2picrylhydrazyl assay, Anti-Parkinson's, Dopamine agonist.

Downloads

Download data is not yet available.

Author Biographies

Preetha Selva, Department of Pharmacology Saveetha Medical College Saveetha University Saveetha Nagar Thandalam Chennai-602105

assistant professor, deparment of pharmacology

Srinivasan Vengadassalapathy, Department of Pharmacology Saveetha Medical College Saveetha University Saveetha Nagar Thandalam Chennai-602105

assistant professor, department of pharmacology

References

Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, et al. Pramipexole in patients with early Parkinsonâ€™s disease (PROUD): A randomised delayed-start trial. Lancet Neurol 2013;12(8):747-55.

Niranjan R. The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinsonâ€™s disease: Focus on astrocytes. Mol Neurobiol 2014;49(1):28-38.

Pain S, Gochard A, Bodard S, Gulhan Z, Prunier-Aesch C, Chalon S. Toxicity of MPTP on neurotransmission in three mouse models of Parkinsonâ€™s disease. Exp Toxicol Pathol 2013;65(5):689-94.

Borah A, Mohanakumar KP. L-DOPA induced-endogenous 6-hydroxydopamine is the cause of aggravated dopaminergic neurodegeneration in Parkinsonâ€™s disease patients. Med Hypotheses 2012;79(2):271-3.

Hattoria N, Wanga M, Taka H, Fujimura T, Yoritaka A, Kubo S, et al. Toxic effects of dopamine metabolism in Parkinsonâ€™s disease. Parkinsonism Relat Disord 2009;15 Suppl 1:S35-8.

Jankovic J. Motor fluctuations and dyskinesias in Parkinsonâ€™s disease: Clinical manifestations. Mov Disord 2005;20 Suppl 11:S11-6.

Bonuccelli U, Pavese N. Dopamine agonists in the treatment of Parkinsonâ€™s disease. Expert Rev Neurother 2006;6(1):81-9.

Le WD, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinsonâ€™s disease? Drugs Aging 2001;18(6):389-96.

Tintner R, Manian P, Gauthier P, Jankovic J. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease. Arch Neurol 2005;62(8):1290-5.

Gottwald MD, Bainbridge JL, Dowling GA, Aminoff MJ, Alldredge BK. New pharmacotherapy for Parkinsonâ€™s disease. Ann Pharmacother 1997;31(10):1205-17.

Brand-Williams W, Cuvelier ME, Berset C. Use of free radical method to evaluate antioxidant activity. Lebensm Wiss Technol 1995;28:25-30.

EA N, Mathew L. A comparative evaluation of antimicrobial and antioxidant properties of Thevetia neriifolia, juss fruit rind extracts. Int J Curr Pharm Res 2014;6(2):47-50.

Sakat S, Juvekar AR, Gambhire MN. In vitro antioxidant and anti-inflammatory activity of methanol extract of Oxalis corniculata Linn. Int J Pharm Pharm Sci 2010;2(1):146-55.

Hauser DN, Hastings TG. Mitochondrial dysfunction and oxidative stress in Parkinsonâ€™s disease and monogenic Parkinsonism. Neurobiol Dis 2013;51:35-42.

Gaki GS, Papavassiliou AG. Oxidative stress-induced signaling pathways implicated in the pathogenesis of Parkinsonâ€™s disease. Neuromolecular Med 2014;16(2):217-30.

Joyce JN, Woolsey C, Ryoo H, Borwege S, Hagner D. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinsonâ€™s disease, and downregulates the dopamine transporter via the D3 receptor. BMC Biol 2004;2:22.

Park G, Park YJ, Yang HO, Oh MS. Ropinirole protects against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced neurotoxicity in mice via anti-apoptotic mechanism. Pharmacol Biochem Behav 2013;104:163-8.

Tanaka K, Miyazaki I, Fujita N, Haque ME, Asanuma M, Ogawa N. Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist. Neurochem Res 2001;26(1):31-6.